23andMe Investor Presentation Deck
Unique 23andMe genetic and phenotypic data platform and insights
Genetics based drug discovery and development
Ability to recontact customers and to conduct real-time research at scale
● Advanced statistical and computational modeling
23andMe Therapeutics Core Capabilities
Fully operational biopharma capabilities
●
●
In vitro and in vivo translational research laboratories
Antibody and protein engineering
CMC, analytics, bio-analytics and quality assurance
Non-clinical and early phase clinical development
Track record of successful target and drug candidate discovery;
an experienced drug development team
Ability to move quickly from target validation to the clinic
Extensive experience in portfolio and alliance management
Focus on delivering value for our partners
Holli
Copyright © 2023 23and Me, Inc.
XX
23and Me
27View entire presentation